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Abstract
Pre-emptive isolation of suspected methicillin-resistant Staphylococcus aureus (MRSA) carriers is considered essential for controlling the
spread of MRSA, but noncolonized patients will be isolated unnecessarily as a result of a delay in diagnosis of 3–5 days with conven-
tional cultures. We determined costs per isolation day avoided, and incremental costs of rapid MRSA screening tests when added to
conventional screening, but with decisions on isolation measures based on PCR results. A prospective multicentre study evaluating BD
GeneOhm MRSA PCR (‘IDI’) (BD Diagnostics, San Diego, CA, USA), Xpert MRSA (‘GeneXpert’) (Cepheid, Sunnyvale, CA, USA) and
chromogenic agar (MRSA-ID) (bioMe´rieux, Marcy-l’Etoile, France) was performed in 14 Dutch hospitals. Among 1764 patients at risk,
MRSA prevalence was 3.3% (n = 59). Duration of isolation was 19.7 and 16.1 h with IDI and GeneXpert, respectively, and would have
been 30.0 and 76.2 h when based on chromogenic agar and conventional cultures, respectively. Negative predictive values (at a patient
level) were 99.5%, 99.1% and 99.5% for IDI, GeneXpert and chromogenic agar, respectively. Numbers of isolation days were reduced
by 60% and 47% with PCR-based and chromogenic agar-based screening, respectively. The cost per test was €56.22 for IDI, €69.62
for GeneXpert and €2.08 for chromogenic agar, and additional costs per extra isolation day were €26.34. Costs per isolation
day avoided were €95.77 (IDI) and €125.43 (GeneXpert). PCR-based decision-making added €153.64 (IDI) and €193.84 (GeneXpert)
per patient to overall costs and chromogenic testing would have saved €30.79 per patient. Rapid diagnostic testing safely reduces
the number of unnecessary isolation days, but only chromogenic screening, and not PCR-based screening, can be considered as cost
saving.
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Introduction
There is considerable geographic variation in the prevalence
of nosocomial methicillin-resistant Staphylococcus aureus
(MRSA) infections, with the lowest incidences in countries
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with a strict MRSA policy, such as Scandinavian countries
and the Netherlands (http://www.rivm.nl/earss/database/).
This strategy includes, among others, pre-emptive isolation
of patients at high risk for MRSA carriage until the absence
of MRSA carriage has been demonstrated. Although pre-
emptive isolation is considered to be a cornerstone of such
a policy [1,2], it is also considered costly, and isolation may
compromise the quality of patient care [3,4]. Moreover,
most patients at risk for carriage will not be colonized with
MRSA, yielding many unnecessary isolation days because con-
ventional microbiological culture methods have a diagnostic
delay of 3–5 days.
New techniques allow rapid screening for MRSA carriage,
which may reduce the logistic and ﬁnancial burden associated
with pre-emptive isolation and may improve the quality of
care for patients. However, the costs and effects of such
tests have not been rigorously determined. Therefore, we
quantiﬁed costs and beneﬁts of three rapid screening tests
for MRSA in a multicentre study in the Netherlands.
Materials and Methods
Study design and setting
A prospective multicentre study was performed in 14 Dutch
hospitals (ﬁve university hospitals, nine teaching hospitals)
between December 2005 and June 2008. The effects of rapid
diagnostic testing for MRSA, added to screening with conven-
tional microbiological culture methods for patients eligible for
MRSA screening, were evaluated. Two real-time PCR assays
were evaluated: BD GeneOhm MRSA PCR (BD Diagnostics,
San Diego, CA, USA) between December 2005 and May 2007
(‘IDI study’), and Xpert MRSA assay (Cepheid, Sunnyvale, CA,
USA) between April 2007 and June 2008 (‘GeneXpert study’)
(Fig. S1). Within the framework of the IDI study, a nested pro-
spective cohort study was performed in ten of the 14 hospi-
tals, between February 2006 and May 2007, to determine the
effects of screening with chromogenic agar (MRSA-ID; bio-
Me´rieux, Marcy-l’Etoile, France) (‘chromogenic study’). How-
ever, the results of the chromogenic agar testing were not
used to change isolation measures because these decisions
were always based on BD GeneOhm MRSA PCR results.
Eligibility for screening was based on the risk proﬁle for
MRSA carriage, as deﬁned in Dutch guidelines (Table S1).
Patients admitted to intensive care units (ICU) were
excluded from the IDI study. Before the study, patients cate-
gorized as at high risk for MRSA carriage were screened and
pre-emptively isolated until conventional microbiological cul-
ture results had demonstrated absence of MRSA. This prac-
tice has been used for more than 20 years and is routine in
all Dutch hospitals. The current intervention implied that
continuation (or discontinuation) of pre-emptive isolation
was decided immediately upon PCR results, which was per-
formed as soon as possible in patients meeting the screening
criteria, mostly at the time of hospital admission. During iso-
lation, patients were nursed in a single-patient room (prefer-
ably with anteroom) and with barrier precautions. In all
participating hospitals, adherence to this policy was con-
trolled by infection control practitioners who actively traced
patients meeting the criteria for screening and provided con-
stant feedback to the wards on the necessity of this policy.
The institutional review board decided that informed con-
sent was not needed.
Study endpoints and data collection
The primary endpoint was the cost per isolation day avoided
and the incremental costs of rapid MRSA screening tests
when added to conventional screening. Computerized
reporting of all steps in the microbiology laboratory and
recording of the time point of start and discontinuation of
isolation by the infection control practitioners allowed the
exact determination of turnaround times (TATs). The num-
ber of additional isolation days, should PCR or chromogenic
testing not have been performed, was determined using the
time of availability of conventional culture results. Isolation
days avoided when using chromogenic agar were calculated
upon the hypothetical scenario that these results had been
used in decision-making on termination of isolation.
To determine cost effectiveness of adding rapid screening
to the Dutch MRSA policy, an economic evaluation, applying
a hospital perspective, was performed. Incremental costs
were calculated and included costs attributed to rapid
screening, costs because of false-negative test results and
costs for isolation days (on a regular ward in a non-outbreak
situation). A detailed description of cost analyses is provided
in Appendix S1.
Microbiological analysis
Samples. Swabs from the anterior nares, throat, perineum
and, if present, wounds, catheter insertion sites, sputum and
urine samples (in case of an indwelling urinary catheter) were
obtained directly after meeting eligibility criteria. Swabs in
liquid Stuart transport medium (Becton Dickinson, Franklin
Lakes, NJ, USA) were used for PCR and these samples were
taken ﬁrst. Subsequently, swabs were taken for conventional
and chromogenic culture. Specimens were transported at
room temperature and refrigerated until processed.
Conventional microbiological MRSA screening. Specimens for
conventional microbiological cultures were processed
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according to the guidelines of the Dutch Society of Medical
Microbiology [5], which includes a broth enrichment step for
all swabs, combined with selective and nonselective agar
plates.
MRSA PCR. During the IDI study, specimens were processed
with the BD GeneOhm MRSA assay run on the SmartCycler
platform (Cepheid). Specimen preparation adaptations were
made for swabs from wounds (50 lL of cell suspension
added to the lysis tube that was not centrifuged) and urine
and pus (ﬁrst centrifuged for 10 min, with the sample buffer
subsequently added to the pellet). The PCR assay was per-
formed with an additional freeze–thaw cycle of the lysates to
reduce inhibitory effects of interfering substances. In the
GeneXpert study, a four-site GeneXpert system (Cepheid)
was used. Nose, throat and perineum specimens were pro-
cessed separately, and additional specimens, when present,
were pooled in the fourth cartridge.
On a patient level, PCR results were considered positive
if at least one PCR result was positive and were considered
negative if the nasal swab and at least one other test result
were negative (and the other sites were negative or noncon-
clusive). In case of a nonconclusive PCR result of the nasal
swab, the overall test result for that patient was considered
as nonconclusive and isolation was continued until conven-
tional cultures were negative or until a second PCR test per-
formed on a new nasal swab was negative. Results, both
positive and negative, were immediately reported to the
wards. MRSA PCR was performed within 24 h, but not dur-
ing weekends and on holidays (except for one hospital during
the IDI study and ﬁve hospitals during the GeneXpert study).
Final results of conventional cultures were considered as
the gold standard. Therefore, isolation measures based upon
a positive PCR result were withdrawn when conventional
culture results were negative.
Chromogenic agar. After inoculation of agar plates for conven-
tional cultures, specimens were plated directly on the
selective chromogenic agar MRSA-ID and interpreted after
18–24 h (also during weekends). Growth of green-pigmented
colonies was considered positive (indicating MRSA) and no
growth or colonies with other colours were considered
negative. Results were not communicated to the patient
wards and did not have consequences for infection control
procedures.
Statistical analysis
Test characteristics were determined on the patient level
based on a combination of results from all anatomical sites
sampled. For determination of test characteristics, patients
were either MRSA-negative (including those with nonconclu-
sive results) or -positive. A detailed microbiological analysis
of the performance of the three tests per specimen is
beyond the scope of the present study. Continuous variables
were compared using the Mann–Whitney U-test; categorical
variables were compared with the chi-squared test and Fish-
er’s exact test.
Results
Patient population
Overall, 1764 patients were included in the PCR studies (853
in the IDI study and 911 in the GeneXpert study; Fig. 1a,b)
yielding 6627 screening samples (1764 nares, 1763 throat,
1763 perineum, 609 wound, 238 urine, 169 catheter insertion
sites and 321 other specimen). The number of patients
included per hospital was in the range 25–374 (Table S2).
Inclusion of eligible patients was >95% in all hospitals. Previous
admission to a foreign hospital was the most important reason
for screening (Table 1). In all, 428 patients, in ten hospitals,
were included in the chromogenic study yielding 1485 samples
(427 nares, 427 throat, 428 perineum, 107 wound, 32 urine,
31 catheter insertion sites and 33 other specimen) (Fig. 1c).
Patient characteristics were comparable for all study groups.
Test characteristics
The prevalence of MRSA carriage, based upon conventional
microbiological cultures, was 3.3% (n = 59 patients)
(Table 1). Using the results of conventional cultures as a ref-
erence, sensitivity, speciﬁcity and positive and negative pre-
dictive values for detecting MRSA at the patient level were
85.2%, 96.5%, 44.2% and 99.5% for BD GeneOhm MRSA
PCR; 75.0%, 94.5%, 33.3% and 99.1% for the Xpert MRSA
assay; and 85.7%, 96.6%, 46.2% and 99.5% for chromogenic
agar testing, respectively.
Effect on pre-emptive isolation
The median duration of isolation was 19.7 h during the IDI
study and 16.1 h during the GeneXpert study; it would
have been 30.0 and 76.2 h when isolation measures had
been based on chromogenic agar and conventional cultures,
respectively (Table 2). Time for samples to arrive at the
microbiology laboratories was longer during the IDI study
than during the GeneXpert and chromogenic studies, prob-
ably as a result of a learning effect (i.e. time interval
reduced by 2.4 h during the IDI study) and because three
hospitals that did not participate in the GeneXpert and
chromogenic studies had an above-average delivery time
(median 15.6 h). The estimated total number of isolation
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days needed, based upon the conventional culture strategy
and incorporating discharge time of patients, was 6112 days.
Pre-emptive isolation was discontinued upon a negative
PCR result in 1528 patients (86.6%; 87.1% in the IDI study
and 86.2% in the GeneXpert study). PCR reduced the num-
ber of isolation days by 60.0% (60.4% in the IDI study and
59.6% in the GeneXpert study) to 2442 days, avoiding 3670
isolation days.
PCR results appeared to be false-negative in 12 of 1764
patients (0.7% overall; 0.5% in the IDI study and 0.9% in the
GeneXpert study) and nine of these patients had been trea-
ted without isolation measures until discharge (n = 4) or
until MRSA was detected in screening cultures (n = 5) for a
total of 23 days. According to protocol, 112 patients and
133 health care workers were screened, and MRSA carriage
was detected in two patients and one health care worker
(all in one contact screening in which it remained uncertain
whether the false-negative case was the index).
One hundred and seventy-two patients (9.8%) remained
in isolation because of a positive (n = 114) or nonconclu-
sive (n = 41) PCR test and 17 remained in isolation for
other reasons. Most of the patients with positive PCR
results (61%; 70/114) appeared to be MRSA-negative with
conventional cultures (56.0% in the IDI study and 66.7% in
the GeneXpert study). In 64 patients (3.6%), the PCR test
results became available after patient discharge (n = 51) or
after the availability of conventional culture results
(n = 13).
TABLE 1. Demographic and clinical characteristics of
patients
Characteristic
IDI
study
(n = 853)
GeneXpert
study
(n = 911)
Chromogenic
study
(n = 428)a
Males, n (%) 467 (54.7) 518 (56.9) 237 (55.4)
Age, mean (range), years 47 (0–95) 48 (0–97) 46 (0–95)
Ward of admission, n (%)
Internal medicine 167 (19.6) 178 (19.5) 72 (16.8)
Surgery 156 (18.3) 176 (19.3) 75 (17.5)
Paediatrics 119 (14.0) 87 (9.5) 65 (15.2)
Cardiology 104 (12.2) 84 (9.2) 55 (12.9)
Neurology 85 (10.0) 71 (7.8) 41 (9.6)
ICU NAb 86 (9.4) NAb
Other 222 (26.0) 229 (25.1) 120 (28.0)
Reason for MRSA suspicion, n (%)
Treatment in foreign hospital 647 (75.8) 578 (63.4) 336 (78.5)
Contact with MRSA carrier 106 (12.4) 183 (20.1) 26 (6.1)
Contact with pigs 65 (7.6) 128 (14.1) 55 (12.9)
Treatment in a Dutch
hospital with MRSA outbreak
22 (2.6) 4 (0.4) 8 (1.9)
Other 13 (1.5) 18 (2.0) 3 (0.7)
MRSA carriage, n (%) 59/1764 (3.3)
Overall 27/853 (3.2) 32/911 (3.5) 13/428 (3.0)
Treatment in foreign hospital 12/647 (1.9) 8/578 (1.4) 7/336 (2.1)
Contact with MRSA carrier 3/106 (2.8) 5/183 (2.7) 0/26 (0)
Contact with pigs 10/65 (15.4) 19/128 (14.8) 6/55 (10.9)
Other 2/35 (5.7) 0/22 (0) 0/11 (0)
ICU, intensive care unit; NA, not applicable; MRSA, methicillin-resistant Staphylo-
coccus aureus.
aCohort from IDI study.
bIntensive care unit (ICU) patients were excluded in the IDI study and the chro-
mogenic study.
864 Assessed for eligibilitya
853 Included
28 MRSA PCR non-conclusiveb773 MRSA PCR – 52 MRSA PCR +
770 Culture – 3 Culture + 27 Culture – 29 Culture – 23 Culture +1 Culture +
911 Included 
14 MRSA PCR non-conclusivea825 MRSA PCR – 72 MRSA PCR +
817 Culture – 8 Culture + 14 Culture – 48 Culture – 24 Culture +0 Culture +
428 Included
1 Chromogenic agar
non-conclusivea401 Chromogenic agar – 26 Chromogenic agar +
400 Culture – 1 Culture + 0 Culture – 14 Culture – 12 Culture +1 Culture +
(a)
(b)
(c)
FIG. 1. (a) Flowchart of patients included in
the IDI study. aContact screening patients
were only assessed when the contact screen-
ing was of limited size as the number of avail-
able slots on the SmartCycler is 14 (maximum
of four patients). bPCR of the nose swab was
unresolved. (b) Flowchart of patients included
in the GeneXpert study. aPCR of the nose
swab was unresolved (n = 12) or the nose
swab was negative and all other sites were
nonconclusive (n = 2). (c) Flowchart of
patients included in the chromogenic study.
aNo chromogenic media of the nose speci-
men.
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Using projected times of patient isolation for conventional
and chromogenic cultures, the estimated total number of
isolation days needed, based upon the conventional culture
strategy (incorporating discharge time of patients) in the
chromogenic study, was 1418 and would have been 746 with
chromogenic agar testing, avoiding 672 isolation days in 344
patients (reduction of 47.4%).
Cost analysis
Costs per test were €56.22 and €69.62 for the BD Gene-
Ohm MRSA PCR and Xpert MRSA assay, respectively, and
€2.08 for chromogenic agar (Table 3). The costs per isola-
tion day avoided were €95.77 in the IDI study, €125.43 in
the GeneXpert study and would have been €6.74 in the
chromogenic study. The additional costs of one extra isola-
tion day on a regular ward in a non-outbreak situation were
estimated to be €26.34 (Table S3) and, therefore, PCR-based
decision-making added €153.64 and €193.84 per patient in
the IDI and GeneXpert study, respectively. With chromo-
genic testing, €30.79 would have been saved per patient. The
results were insensitive to varying the costs of an isolation
day between €26.34 and €70.41. In threshold analyses, the
use of BD GeneOhm MRSA PCR and the Xpert MRSA essay
would become cost-effective when PCR costs are reduced
to €14.12 and €11.63, respectively. PCR-based screening
would become cost-saving when the costs of an isolation day
are higher than €95.77 and €125.43 for the IDI study and
the GeneXpert study, respectively.
Discussion
In a low endemic setting for MRSA, and using a strategy of
screening and pre-emptive isolation of high-risk patients, the
addition of PCR-based screening reduced the number of iso-
lation days needed by 60% at a cost of €95.77 or €125.43
per isolation day avoided, depending on the MRSA PCR
used. The projected beneﬁts of chromogenic testing were a
reduction of 47% of isolation days at a cost of €6.74 per iso-
lation day avoided. Because the estimated cost per isolation
day in our setting was €26.34, chromogenic screening, but
not PCR-based screening, can be considered as a cost-saving
procedure.
Nationwide policies to control nosocomial spread of
MRSA have been successful in the Netherlands and Scandina-
vian countries [6]. Although such policies consist of different
measures, the pre-emptive isolation of patients with high risk
of MRSA carriage appears to be critical [2]. However, patient
isolation is considered cumbersome for hospital staff and has
been associated with a reduced quality of patient care [4,7].
Limiting the number of unnecessary isolation days, therefore,
could be an important measure for improving the feasibility
and acceptance of pre-emptive isolation as well as the quality
of patient care. The results obtained in the present study
demonstrate that both PCR- and chromogenic agar-based
testing can be used safely to discontinue pre-emptive isola-
tion. Naturally, the ﬁndings are based on the conditions
TABLE 2. Turnaround times of screening methods; values are expressed as medians (interquartile range)
Turnaround times
IDI study
BD GeneOhm
MRSA PCR
(n = 853)
GeneXpert study
Xpert MRSA assaya
(n = 911)
Conventional
cultureb
(n = 1764)
Chromogenic
agar
(n = 428)
Time from start of isolation to delivery
of specimen to laboratory (h)c
8.2 (1.3–17.0)d 5.0 (1.0–16.6)d 7.0 (1.0–16.9) 4.8 (0.7–14.6)d
Time from arrival in the laboratory
to deﬁnite result (h)e
3.6 (2.2–6.7) 2.0 (1.5–3.3) 74.0 (67.6–96.0) f
Time from deﬁnite test result
to discontinuation of isolation (h)
0.2 (0–0.5) 0.3 (0.2–0.5) 0.3 (0.2–0.5)g 0.2 (0–0.5)g
Time from start of isolation
to deﬁnite test result (h)h
17.8 (5.0–24.2) 14.0 (3.4–21.2) 89.9 (71.4–111.3) 31.9 (24.7–41.5)
Duration of isolation (h) 19.7 (6.0–34.6) 16.1 (4.0–24.7) 76.2 (50.0–96.8) 30.0 (24.2–43.0)
MRSA, methicillin-resistant Staphylococcus aureus.
aIn 44 patients (4.8%), the exact moment of the start or discontinuation of isolation was not known.
bTurnaround times of conventional cultures during the IDI study: time from start of isolation to delivery of specimen to laboratory: 8.2 h (1.3–17.0); time from arrival in the
laboratory to deﬁnite result: 76.8 h (69.6–97.7); time from deﬁnite test result to discontinuation of isolation: 0.2 h (0–0.5); time from start of isolation to deﬁnite test result:
92.4 h (73.8–112.8); duration of isolation 85.3 h (58.1–99.4). Turnaround times of conventional cultures during GeneXpert study: time from start of isolation to delivery of
specimen to laboratory 5.0 h (1.0–16.6); time from arrival in the laboratory to deﬁnite result 72.0 h (66.5–94.6); time from deﬁnite test result to discontinuation of isolation
0.3 h (0.2–0.5); time from start of isolation to deﬁnite test result 87.6 h (70.0–105.5); duration of isolation: 71.8 h (46.7–93.8).
cWhen not all of the specimens arrived simultaneously, the time of last specimen to arrive was noted.
dFor an explanation of this difference, see text.
eIncluding weekends and public holidays when the MRSA PCR was not performed in all hospitals.
fChromogenic agar was read 18–24 h after inoculation; the exact time was not noted.
gAssuming time of reporting results of conventional cultures and chromogenic tests would have been similar to the observed time for notiﬁcation of PCR results.
hBecause some patients had already been discharged when the results became available, the isolation duration is shorter than time until the deﬁnite test result for chromo-
genic agar and conventional culture.
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employed in the present study. The cost per isolation day
avoided with PCR may decrease with lower material costs,
increased test sensitivity and shorter TATs, which would fur-
ther reduce the number of isolation days. Furthermore, we
have evaluated the costs of both methods when added to an
existing policy of search and destroy, and therefore did not
include the isolation costs for patients with documented
MRSA carriage and the construction costs for isolation facili-
ties. The estimated cost per isolation day in our setting
(€26.34) corresponds to the costs reported in other studies
[8,9]. Although PCR methods may yield results within 2 h in
the laboratory, reported TATs in clinical studies are in the
range 13–23 h [1,10–12], which is quite similar to our obser-
vations. TATs could be shortened if laboratories would per-
form PCR outside ofﬁce hours, although this would also
increase the cost per procedure.
The results obtained in the present study partly contrast
with the experiences in a single-centre study in Switzerland
[9], where replacement of chromogenic agar testing by PCR-
based testing reduced the number of pre-emptive isolation
days by 54% and was considered cost saving. However, a
comparison of our ﬁndings is difﬁcult because the median
TATs in that study were 7 and 3 days for chromogenic test-
ing and PCR, respectively, with a cost per PCR of €10 only,
and it is not clear how patients who had already been
discharged when test results became available were incorpo-
rated in the analysis.
Is our experience in a low endemic setting generalizable
to settings with higher MRSA prevalence, where universal
screening at hospital admission has been proposed [13]?
Reported MRSA prevalence rates among patients at the time
of hospital admission in studies on universal MRSA screening
are in the range 2.7–10.2% [12,14–17], which is comparable
or slightly higher than the prevalence of 3.3% in our selected
high-risk population. Therefore, our ﬁndings may well
account for scenarios of universal screening in high-endemic
settings. Yet there are additional investment costs for isola-
tion rooms when rapid diagnostic testing and pre-emptive
isolation are applied to situations with a higher MRSA preva-
lence, this may be partly balanced by a reduction in price
per test with large-volume testing [18,19]. In addition, if
conventional culturing is not added to screening with PCR
or chromogenic agar, false-positive results will increase the
numbers of patients in isolation, as well as costs.
The present study has several limitations, such as the quasi-
experimental design of the PCR intervention study and the
hypothetical nature of the nested cohort study with chromo-
genic agar testing. However, we have no evidence of selection
bias because >95% of eligible patients were included. Another
limitation is that only the GeneXpert study included ICU
TABLE 3. Costs of adding rapid diagnostic testing of methi-
cillin-resistant Staphylococcus aureus (MRSA) to the cur-
rently used MRSA policy
Resource unit
Number
of units
Cost/unit (€) Additional
cost (€)
BD GeneOhm MRSA PCRa
Cost per testb 30.49
Additional costsc 0.75
Platform costs (SmartCycler)d 16.01
Personnel costse 8.97
Total cost per unit 56.22
Total cost of test strategy
in the present study
3113 175 012.86
PCR cost per patient tested
(n = 853)
205.17
Total cost of false-negative PCR
results
4 1441.13 5764.52
Total additional costs 180 777.38
Xpert MRSA assay
Cost per testb 42.84
Additional costsc 0.75
Platform costs (GeneXpert)d 23.93
Personnel costse 2.10
Total cost per unit 69.62
Total cost of test strategy
in the present study
3045 211 992.90
PCR cost per patient tested
(n = 911)
232.70
Total costs of false negative PCR
results
8 1441.13 11 529.04
Total additional costs 223 521.94
MRSA-ID, bioMe´rieuxf
Cost per test 1.40
Personnel and additional
costs for one extra plate
0.68
Total cost per unit 2.08
Total cost of test strategy
in this study
1485 3088.80
Chromogenic agar cost
per patient tested (n = 428)
7.22
Total costs of false-negative
chromogenic agar test result
1 1441.13 1441.13
Total additional costs 4529.93
Extra costs attributable to contact
screening and isolation because
of a false-negative PCR resultg
1441.13
Screening of patientsh 11.2 63.30 708.96
Screening of health care workersi 13.3 34.86 463.64
Additional working time (h)j 4 25.94 119.97
Isolation days (day)k 5.64 26.34 148.56
aCost per PCR when 200 patients per year are screened.
bCost platform not included.
cAdditional costs include: Liquid Stuart’s swabs, gloves, consumables.
dPrice SmartCycler €41,650, price GeneXpert €63,813.75, depreciation in
5 years, 8% maintenance costs.
eLaboratory staff and medical microbiologist included. Based on hands on time
of laboratory staff of 80 min per run for BD GeneOhm MRSA PCR and 15 min
per run for Xpert MRSA assay.
fWhen chromogenic agar is added to standard cultures.
gMean of contact screenings because of ten false-negative MRSA PCR results
during the study (of two cases consequences are unknown).
hIncludes two screenings per patient at four sites (nose, throat, perineum and
other) using standard cultures.
IIncludes two screenings per health care worker at two sites (nose, throat)
using standard cultures.
jIn three contact screenings, 40 extra working hours were noted for infection
control practitioners and nurses; the average nurse wage costs €25.94 per hour
based on gross salary including taxes and social premiums; assuming 13.3 h pre-
mium pay for work during evening and nightshift with average nurse wage costs
of €38.13 per hour.
kContact screening of patients was performed in ﬁve of the false-negative
PCR results and, because isolation measures are only instituted for room-
mates, we assumed 15 contact patients were isolated (three per contact
screening). Median time of isolation when based on standard cultures during
the study would have been 3.76 days; this was used to calculate the costs of
isolation for screened patients. Cost includes all costs attributed to isolation
precautions for hospitalized patients on a regular ward (i.e. supplies, time
attributable to isolation precautions for nurse and physician, additional
cleaning costs).
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patients, yet the exclusion of ICU patients did not change the
results obtained. In addition, the 12 false-negative cases in the
present study may not reﬂect the entire spectrum of conse-
quences of missing an MRSA carrier with rapid screening.
However, because the total costs of false-negative screening
outcomes are relatively low, this uncertainty is not likely to
change the conclusions made in our study.
Importantly, for scientiﬁc or economic reasons, the extre-
mely positive perception by hospital staff of the reduced
duration of patient isolation would make a return to the old
situation impossible. Whether the extra costs of rapid
testing are balanced by the positive effects in terms of staff
and patient satisfaction could be the subject of future cost-
effectiveness studies.
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